In today’s recent session, 3.38 million shares of the Lineage Cell Therapeutics Inc (AMEX:LCTX) have been traded, and its beta is 1.27. Most recently the company’s share price was $0.70, and it changed around -$0.2 or -22.04% from the last close, which brings the market valuation of the company to $132.96M. LCTX at last check was trading at a discount to its 52-week high of $1.61, offering almost -130.0% off that amount. The share price’s 52-week low was $0.77, which indicates that the recent value has fallen by an impressive -10.0% since then. We note from Lineage Cell Therapeutics Inc’s average daily trading volume that its 10-day average is 0.54 million shares, with the 3-month average coming to 417.28K.
Lineage Cell Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.43. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended LCTX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Lineage Cell Therapeutics Inc is expected to report earnings per share of -0.04 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Instantly LCTX has been showing red trend so far today with a performance of -22.04% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.9484 on recent trading dayincreased the stock’s daily price by 26.19%. The company’s shares are currently down -35.40% year-to-date, but still down -22.88% over the last five days. On the other hand, Lineage Cell Therapeutics Inc (AMEX:LCTX) is -20.50% down in the 30-day period. We can see from the shorts that 15.94 million shares have been sold at a short interest cover period of 35.21 day(s).
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Lineage Cell Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -32.94 percent over the past six months and at a -25.00% annual growth rate that is well below the industry average of 18.10%. The year-over-year growth rate is expected to be -11.01%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 1.66M in revenue for the current quarter. 4 analysts expect Lineage Cell Therapeutics Inc to make 1.02M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.12M and 1.44M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -21.78%. Forecasts for the next quarter put sales growth at -29.31%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.25%.
LCTX Dividends
Lineage Cell Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.44% of Lineage Cell Therapeutics Inc shares, and 50.56% of them are in the hands of institutional investors. The stock currently has a share float of 50.79%. Lineage Cell Therapeutics Inc stock is held by 143.0 institutions, with BROADWOOD CAPITAL INC being the largest institutional investor. By 2024-06-30, it held 22.7798% of the shares, which is about 41.67 million shares worth $41.55 million.
BLACKROCK INC., with 5.2264% or 9.56 million shares worth $9.53 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Jun 30, 2024. The former held 4.42 shares worth $3.12 million, making up 2.34% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 3.72 shares worth around $2.63 million, which represents about 1.97% of the total shares outstanding.
